» Articles » PMID: 29423057

Interleukin-34 Sustains Pro-tumorigenic Signals in Colon Cancer Tissue

Abstract

Interleukin-34 (IL-34), a cytokine produced by a wide range of cells, binds to the macrophage colony-stimulating factor receptor (M-CSFR-1) and receptor-type protein-tyrosine phosphatase zeta (PTP-z) and controls myeloid cell differentiation, proliferation and survival. various types of cancers over-express IL-34 but the role of the cytokine in colorectal cancer (CRC) remains unknown. We here investigated the expression and functional role of IL-34 in CRC. A more pronounced expression of IL-34 was seen in CRC samples as compared to matched normal/benign colonic samples and this occurred at both RNA and protein level. Immunohistochemical analysis of CRC tissue samples showed that both cancer cells and lamina propria mononuclear cells over-expressed IL-34. Additionally, CRC cells expressed both M-CSFR-1 and PTP-z, thus suggesting that CRC cells can be responsive to IL-34. Indeed, stimulation of DLD-1 cancer cells with IL-34, but not with MSCF1, enhanced the cell proliferation and cell invasion without affecting cell survival. Analysis of intracellular signals underlying the mitogenic effect of IL-34 revealed that the cytokine enhanced activation of ERK1/2 and pharmacologic inhibition of ERK1/2 abrogated IL-34-driven cell proliferation. Consistently, IL-34 knockdown in HT-29 cells with a specific IL-34 antisense oligonucleotide reduced ERK1/2 activation, cell proliferation and enhanced the susceptibility of cells to Oxaliplatin-induced death. This is the first study showing up-regulation of IL-34 in CRC and suggesting a role for this cytokine in colon tumorigenesis.

Citing Articles

CSF-1R in Cancer: More than a Myeloid Cell Receptor.

Cersosimo F, Lonardi S, Ulivieri C, Martini P, Morrione A, Vermi W Cancers (Basel). 2024; 16(2).

PMID: 38254773 PMC: 10814415. DOI: 10.3390/cancers16020282.


A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.

Han N, Wada H, Kobayashi T, Otsuka R, Seino K Oncoimmunology. 2023; 12(1):2238499.

PMID: 37533702 PMC: 10392724. DOI: 10.1080/2162402X.2023.2238499.


Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.

Alshaebi F, Safi M, Algabri Y, Al-Azab M, Aldanakh A, Alradhi M Front Oncol. 2023; 13:1099696.

PMID: 36798830 PMC: 9927403. DOI: 10.3389/fonc.2023.1099696.


Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.

Monteleone G, Franze E, Maresca C, Colella M, Pacifico T, Stolfi C Cancers (Basel). 2023; 15(3).

PMID: 36765929 PMC: 9913481. DOI: 10.3390/cancers15030971.


Interleukin-34 deficiency aggravates development of colitis and colitis-associated cancer in mice.

Liu Z, Chen W, Wang Y, Chen B, Liu Y, Cheng T World J Gastroenterol. 2023; 28(47):6752-6768.

PMID: 36620338 PMC: 9813936. DOI: 10.3748/wjg.v28.i47.6752.


References
1.
Eda H, Shimada H, Beidler D, Monahan J . Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts. Rheumatol Int. 2010; 31(11):1525-30. DOI: 10.1007/s00296-010-1688-7. View

2.
Cui G, Yuan A, Goll R, Florholmen J . IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand J Gastroenterol. 2012; 47(11):1304-12. DOI: 10.3109/00365521.2012.725089. View

3.
Byrne P, Guilbert L, Stanley E . Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. J Cell Biol. 1981; 91(3 Pt 1):848-53. PMC: 2112824. DOI: 10.1083/jcb.91.3.848. View

4.
Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

5.
Ma X, Lin W, Chen Y, Stawicki S, Mukhyala K, Wu Y . Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure. 2012; 20(4):676-87. DOI: 10.1016/j.str.2012.02.010. View